Search Results
Feb 09, 2026, 07:00 ET Lilly to acquire Orna Therapeutics to advance cell therapies
therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based
More news about: Eli Lilly and Company
Feb 06, 2026, 12:09 ET New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally
WorkstationPoster: 1209-EAutomation of NEBNext® Ultra™ II RNA Library Prep Kit for Illumina® and the NEBNext® Poly(A) mRNA Magnetic Isolation Module® on SPT LabTech firefly® Workstation at Weil Cornell Medical School Genomics CoreFor more information and a list
More news about: New England Biolabs, Inc.
Feb 06, 2026, 08:00 ET Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Feb 06, 2026, 00:10 ET 雲頂新耀宣佈中國國家藥品監督管理局批准維適平®用於治療中重度潰瘍性結腸炎的新藥上市許可申請
MPA）和歐洲藥品管理局（EMA）的 GMP 要求及世界衛生組織（WHO）PQ 標準建設。公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研 mRNA 平台為基礎，持續推進mRNA in vivo CAR-T 與 mRNA 腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：
More news about: 雲頂新耀
Feb 05, 2026, 21:26 ET Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization
More news about: Akeso, Inc.
Feb 05, 2026, 18:30 ET 全球首研的艾美無血清迭代狂苗順利通過註冊現場檢查並上市在即
細胞狂犬疫苗到人二倍體細胞狂犬疫苗、無血清狂犬疫苗，再到 mRNA狂犬疫苗的迭代升級，充分展現了其把握市場趨勢和滿足臨床需求的能力。這一戰略不僅提升了公司的市場份額，還顯著增強了產品定價能力和盈利能力。湘財證券今年1月發佈的觀點認為，產品的市場需求、管線的創新能力將是疫苗企業的核心競爭力。復星國際證券研報就明確指出，人二倍體細胞狂犬病疫苗的單價可達 Vero 細胞狂犬病疫苗的 4-5 倍，預計公司狂犬病疫苗產品線銷售額將會快速增長。憑藉在無血清狂犬疫苗和 mRNA 狂犬病疫苗領域的先發優勢，艾美疫苗未來有望佔據全球市場份額的三分之一以上。由此看來，艾美即將上市的無血清迭代狂苗，憑藉其顛覆性的技術優勢，有望為公司帶來業績的大幅提升。
More news about: 艾美疫苗
Feb 05, 2026, 08:00 ET Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors
Feb. 5, 2026 /PRNewswire/ - Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors, is pleased to welcome
More news about: Providence Therapeutics Holdings Inc
Feb 04, 2026, 19:08 ET 雲頂新耀宣佈與麥科奧特達成MT1013獨家商業化許可協議
MPA）和歐洲藥品管理局（EMA）的 GMP 要求及世界衛生組織（WHO）PQ 標準建設。公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研 mRNA 平台為基礎，持續推進mRNA in vivo CAR-T 與 mRNA 腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網： www.everestmedicines.com。關於麥科奧特
More news about: 雲頂新耀
Feb 04, 2026, 08:00 ET Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
Feb. 4, 2026 /PRNewswire/ - Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors. The PaedNEO-VAX
More news about: Providence Therapeutics Holdings Inc
Feb 03, 2026, 08:00 ET CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Feb 03, 2026, 06:30 ET Deep EigenMatics Ranks #1 Globally in AI Drug Discovery, Outpacing All of Big Pharma in 2025 Patent Output
"Drug Discovery" OR Protein OR Peptide OR "Amino Acid" OR Ligand OR Pharma* OR "small molecule" OR compound OR antibody OR anti-body OR vaccine OR mRNA) NEAR15 (AI OR AI/ML OR "Artificial Intelligence" OR "neural network" OR "Machine Learning" OR "Deep Learning" OR "Generative" OR Deep OR "Reinforcement
More news about: Deep EigenMatics
Feb 02, 2026, 20:00 ET Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
neglected tropical diseases (NTDs).2 Investment of JPY 648 million (approx. USD 4.1 million1) for development of an mRNA vaccine to reduce infection and transmission of vivax malariaMalaria caused by Plasmodium vivax remains a major challenge to malaria
More news about: GHIT Fund
Feb 02, 2026, 20:00 ET Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
neglected tropical diseases (NTDs).2 Investment of JPY 648 million (approx. USD 4.1 million1) for development of an mRNA vaccine to reduce infection and transmission of vivax malariaMalaria caused by Plasmodium vivax remains a major challenge to malaria
More news about: GHIT Fund
Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
26About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation,
More news about: CREATE Medicines, Inc.
Feb 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for February 2026
Blood and Beyond: Unlocking Biological Insights from Novel Sample TypesCELL AND GENE THERAPYFeb 5 - Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T DevelopmentCLINICAL TRIALSFeb 3 - Decoding Alzheimer's disease: trial designs, biomarker breakthroughs,
More news about: Xtalks
Jan 29, 2026, 08:05 ET Skyhawk Therapeutics 公佈其用於治療 Huntington 疾病的藥物 SKY-0515 於第 1 期臨床試驗中 受試患者的九個月中期結果。
SKY-0515 可使血液中的 mHTT 蛋白呈現劑量依賴性降低，在 9 毫克劑量下減幅達 62%，同時 PMS1 mRNA 劑量依賴性降低 26%。 PMS1 是體細胞 CAG 重複序列擴張和 HD 病理的關鍵驅動因素。 SKY-0515 亦表現出優異的中樞神經系統藥物暴露度，整體上安全且耐受性良好。在 SKY-0515 第 1 期臨床試驗 C 部分患者群組中，接受 SKY-0515 治療的患者在 3
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:48 ET A Skyhawk Therapeutics anuncia resultados provisórios de nove meses em pacientes de seu ensaio clínico de fase 1 do SKY-0515 como tratamento para a doença de Huntington
tratamento com SKY-0515 provoca uma redução dependente da dose da proteína mHTT no sangue de 62% com a dose de 9 mg e uma redução da dose dependente do mRNA PMS1 de 26%. O PMS1 é um fator determinante da expansão da repetição somática CAG e da patologia da DH. O SKY-0515 também demonstrou excelente exposição
More news about: Skyhawk Therapeutics
Jan 28, 2026, 23:51 ET Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
Alzheimer's treatment Kisunla, AstraZeneca/Daiichi Sankyo's ADC Datroway, Novartis' antisense oligonucleotide Pelacarsen, and Moderna/Merck's personalized mRNA cancer vaccine intesmeran autogene. Other featured assets include Gilead Sciences/Arcellx's CAR-T therapy anito-cel, Roche's oral SERD Giredestrant,
More news about: Akeso, Inc.
Jan 28, 2026, 20:00 ET Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening
More news about: Nona Biosciences
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
zu einer dosisabhängigen Verringerung des mHTT-Proteins im Blut um 62 % bei einer Dosis von 9 mg und zu einer dosisabhängigen Verringerung der PMS1-mRNA um 26 %. PMS1 ist ein Schlüsselfaktor für die somatische CAG-Repeat-Expansion und die HD-Pathologie. SKY-0515 hat ebenfalls eine hervorragende Exposition
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
Pengobatan dengan SKY-0515 yang bergantung pada dosis menghasilkan penurunan protein mHTT dalam darah sebesar 62% pada dosis 9 mg, dan penurunan mRNA PMS1 sebesar 26% yang bergantung pada dosis. PMS1 adalah pendorong utama ekspansi pengulangan CAG somatik dan patologi HD. SKY-0515 juga telah menunjukkan
More news about: Skyhawk Therapeutics
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
received FDA Fast Track designation for BNT113, an investigational mRNA cancer immunotherapy, for the treatment of patients with human papillomavirus type 16 positive head and neck squamous cell carcinoma (HNSCC) expressing
More news about: USA News Group
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
diseases long constrained by the blood–brain barrier. Looking ahead, the platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease, stroke, and other CNS disorders, significantly advancing the fields
More news about: China Medical University Hospital
Jan 28, 2026, 07:00 ET Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
Léčba přípravkem SKY-0515 vede v závislosti na dávce ke snížení obsahu proteinu mHTT v krvi o 62 % a k redukci mRNA PMS1 o 26 % při dávce 9 mg. PMS1 je klíčovým faktorem expanze somatických CAG repetic a patologie HD. Přípravek SKY-0515 rovněž prokázal vynikající
More news about: Skyhawk Therapeutics